Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Broadcom
AVGO
|
+$784M |
| 2 |
Amgen
AMGN
|
+$695M |
| 3 |
Eli Lilly
LLY
|
+$512M |
| 4 |
Apple
AAPL
|
+$485M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$471M |
Top Sells
| 1 |
Adobe
ADBE
|
+$935M |
| 2 |
NVIDIA
NVDA
|
+$837M |
| 3 |
TJX Companies
TJX
|
+$533M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$364M |
| 5 |
Starbucks
SBUX
|
+$357M |
Sector Composition
| 1 | Technology | 35.94% |
| 2 | Healthcare | 18.89% |
| 3 | Consumer Discretionary | 9.38% |
| 4 | Financials | 9.11% |
| 5 | Industrials | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Carlisle Companies
CSL
$16.8B
| $136M | 0.07% |
334,410
-89,977
| -21% | -$36.5M |
|
227
EnerSys
ENS
$3.92B
| $135M | 0.07% |
1,307,582
+1,077
| +0.1% | +$111K |
|
228
Neurocrine Biosciences
NBIX
$14.3B
| $134M | 0.07% |
971,203
-407,310
| -30% | -$56.1M |
|
229
Structure Therapeutics
GPCR
$1.2B
| $132M | 0.07% |
3,354,269
+1,277,569
| +62% | +$50.1M |
|
230
Amicus Therapeutics
FOLD
$2.46B
| $131M | 0.07% |
13,231,394
-583,120
| -4% | -$5.78M |
|
231
United Therapeutics
UTHR
$17.8B
| $131M | 0.07% |
410,010
-225,337
| -35% | -$71.8M |
|
232
Moody's
MCO
$91B
| $130M | 0.07% |
308,246
+278,886
| +950% | +$117M |
|
233
EOG Resources
EOG
$64.2B
| $128M | 0.07% |
1,018,357
-26,748
| -3% | -$3.37M |
|
234
Novo Nordisk
NVO
$241B
| $128M | 0.07% |
893,597
-424,113
| -32% | -$60.5M |
|
235
Keysight
KEYS
$29.1B
| $125M | 0.07% |
916,376
-264,460
| -22% | -$36.2M |
|
236
STAG Industrial
STAG
$6.84B
| $125M | 0.07% |
3,463,614
-528,892
| -13% | -$19.1M |
|
237
Arista Networks
ANET
$176B
| $124M | 0.07% |
1,416,852
-3,808
| -0.3% | -$334K |
|
238
AstraZeneca
AZN
$253B
| $124M | 0.07% |
1,584,052
-148,154
| -9% | -$11.6M |
|
239
S&P Global
SPGI
$167B
| $123M | 0.07% |
275,528
+16,802
| +6% | +$7.5M |
|
240
ITT
ITT
$13.5B
| $119M | 0.06% |
924,444
-102,318
| -10% | -$13.2M |
|
241
IBM
IBM
$239B
| $119M | 0.06% |
687,923
-29,279
| -4% | -$5.06M |
|
242
Welltower
WELL
$113B
| $119M | 0.06% |
1,136,439
-273,005
| -19% | -$28.5M |
|
243
Ares Management
ARES
$38.7B
| $117M | 0.06% |
875,781
+41,166
| +5% | +$5.49M |
|
244
Constellium
CSTM
$2B
| $116M | 0.06% |
6,151,984
-4,171,380
| -40% | -$78.6M |
|
245
Western Alliance Bancorporation
WAL
$9.86B
| $114M | 0.06% |
1,821,421
+204,130
| +13% | +$12.8M |
|
246
Public Storage
PSA
$51.7B
| $114M | 0.06% |
397,222
+376,141
| +1,784% | +$108M |
|
247
Gilead Sciences
GILD
$144B
| $114M | 0.06% |
1,663,494
-50,249
| -3% | -$3.45M |
|
248
Zai Lab
ZLAB
$3.49B
| $113M | 0.06% |
6,527,567
+2,099,556
| +47% | +$36.4M |
|
249
Zurn Elkay Water Solutions
ZWS
$7.82B
| $113M | 0.06% |
3,827,269
-37,859
| -1% | -$1.11M |
|
250
Western Digital
WDC
$32.4B
| $111M | 0.06% |
1,933,219
+1,877,179
| +3,350% | +$108M |
|